← Leaderboards
Suyong Choi
University Of Nebraska Medical Center
$1,627,271
Attributed
$1,627,271
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $510.2K · FY2022–25$1M$750K$500K$250K$0
'22
'23
'24
'25
Funding mix
By agency
NIH$1,627,271 · 3
By mechanism
R35$1,104,922 · 1
P20$368,849 · 1
R03$153,500 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Nebraska Medical Center
Same institution · by research overlap
- Amarnath Natarajan$8,497,174
- Maneesh Jain$6,905,007
- Michael A Hollingsworth$34,707,253
- Ravi Salgia$9,622,551
- Terry D Hexum$917,596
Others in their field
Other Rising Stars on “Signal Transduction”
- Suma Babu · Massachusetts General Hospital$20,303,231
- Sabrina Paganoni · Massachusetts General Hospital$20,303,231
- Thomas K Karikari · Wake Forest University Health Sciences$12,972,426
- Gregory Sorenson · University Of Maryland Baltimore County$9,161,697
- Charles Daniel Meyers · Tempero Bio, Inc.$5,310,920
- Ian Gurrell · Astrazeneca Pharmaceuticals, Lp$5,256,914
Research focus
Signal TransductionBiochemicalMolecularRegulationProteinsPhosphatidylinositolsPathogenesisMediatingCellsLipidsPhosphotransferasesBiologicalComplexGene ExpressionNuclearCell NucleusCell PhysiologyHuman Disease1-Phosphatidylinositol 4-KinaseMalignant NeoplasmsEnzymesFunctional DisorderGenetic CorepressorGenome-Wide
Grant awards (5)
Unexpected roles of phosphoinositides in the nucleus$383,750
R35 · FY2025 · GM · contact PI
Unexpected roles of phosphoinositides in the nucleus$364,490
R35 · FY2024 · GM · contact PI
Unexpected roles of phosphoinositides in the nucleus$356,682
R35 · FY2023 · GM · contact PI
PIP5K1A is a novel mutant KRAS effector and essential for pancreatic cancer cell survival$153,500
R03 · FY2023 · TR · contact PI
Novel Mechanisms of Nuclear Phosphoinositide Signaling in Regulation of the YAP/TAZ Pathway in Triple-negative Breast Cancer$368,849
P20 · FY2022 · GM · contact PI